Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 39Lymphoid 35Myeloid 27Plasma cell 14Classical hematology 11Dermatologic 4Sarcoma 2Genitourinary 2Gastrointestinal 2CNS 2Breast 2Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Lacrimal Apparatus Diseases 1Lacerations 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endophthalmitis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cyclosporins × Gynecologic × Clear all
NCT00824811 2012-08-02

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

M.D. Anderson Cancer Center

Phase 2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Lacrimal Apparatus Diseases, Lung Neoplasms, Endophthalmitis, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Lacerations, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡